CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0615 (clinicaltrials.gov NCT No: NCT00954941)
Title:Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron plus aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine
Principal Investigator:Jorge Cortes
Treatment Agent:Aprepitant; Ondansetron
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the effectiveness of
receiving a combination of ondansetron and aprepitant to receiving ondansetron
alone in helping to prevent nausea and/or vomiting in patients with AML or
HR-MDS who are receiving cytarabine. The safety of this drug combination will
also be studied.

Hide details for General InformationGeneral Information

Disease Group:Hematologic Disorder
Phase of Study:Phase II
Treatment Agents:Aprepitant
Ondansetron
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:n/a
Supported By:Merck
Return Visit:none
Home Care:n/a


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults